• BMY

Earnings call: Bristol-Myers Squibb reports robust Q3 growth, raises guidance

Bristol-Myers Squibb reports a 20% revenue increase, FDA approvals, and strong guidance for growth while navigating challenges from generics and operational efficiency.

• BMY

Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up

Bristol-Myers Squibb raised its 2024 earnings guidance after Q3 results exceeded expectations, with EPS at $1.80 and revenue hitting $11.9 billion, driven by U.S. growth.

• BMY

Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs

Bristol Myers Squibb reported Q3 earnings of $3.7 billion, driven by strong drug sales and raised its full-year forecast to 75-95 cents per share.

• BMY

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug

Bristol Myers Squibb's $6.4 billion lawsuit over alleged FDA approval delays for Breyanzi was dismissed due to improper trustee appointment by UMB Bank for CVR holders.

• BMY

Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment

• BMY
• COST
• DG
• ESTA
• HPQ
• SAVA
• UDMY
• WYNN

Costco dips premarket; Bristol-Myers Squibb, Wynn Resorts rise

US stock futures were steady while investors awaited economic data. Key stock movers included Costco, Bristol-Myers Squibb, and Wynn Resorts, highlighting mixed earnings and regulatory news.

• AMGN
• AZN
• BMY
• JNJ
• MRK
• PFE

US will still pay at least twice as much after negotiating drug prices

The U.S. negotiated drug prices under Medicare remain significantly higher than those in other wealthy nations, highlighting disparities in healthcare costs and market dynamics.